Urinary estrogens as a non-invasive biomarker of viable pregnancy in the giant panda (Ailuropoda melanoleuca)

Kirsten S. Wilson1, Jella Wauters2,3,4, Iain Valentine5, Alan McNeilly1, Simon Girling5, Rengui Li6, Desheng Li6, Hemin Zhang6, Mick T. Rae7, Forbes Howie1, Ruth Andrew8 & William Colin Duncan1

Female giant pandas show complex reproductive traits, being seasonally monoestrus, displaying a variable length embryonic diapause and exhibiting pseudopregnancy. Currently, there is no confirmatory non-invasive biomarker of blastocyst implantation or pregnancy. This study aimed to monitor urinary estrogens across gestation in pregnancy (n = 4), pseudopregnancy (n = 4) and non-birth cycles (n = 5) in the giant panda. A pregnancy-specific profile of estrogens corrected for urinary specific gravity was identified during the gestation period. Pregnant females showed increasing concentrations of estrogens for 29 days until birth, no increase was observed during pseudopregnancy and the two profiles were distinguishable from each other for the final 2 weeks of the cycle suggesting the estrogens are of placental origin. This allowed a nomogram, starting at a known fixed point during the cycle, to be created and tested with cycles of known outcome, and cycles which were inseminated but did not result in a birth. Non-birth profiles showed deviations from that of pregnancy. We believe these deviations indicate the point of failure of the placenta to support a developing cub. Non-invasive longitudinal monitoring of estrogen concentrations therefore has the potential to be developed as a panda pregnancy test to predict viable cub development.
believed to occur during the secondary P4 rise. The peak P4 in the secondary rise is associated with a prostaglandin surge and there is a marked spike of urinary 13,14-dihydro-15-keto-prostaglandin F2α (PGFM) in the urine. After this, urinary P4 decreases and birth is expected within three weeks.

However, giant pandas also undergo pseudopregnancy; the luteal phase of all ovulating female pandas displays the same biphasic P4 profile and urinary PGFM surge during the secondary rise, independent to pregnancy. Therefore, detecting a true ongoing pregnancy in giant pandas can be challenging. Fetal detection through ultrasound has proven successful in some cases, however the procedure requires cooperation from the panda which is often challenging during the final weeks of the cycle. Urinary ceruloplasmin has been suggested as a marker of successful conception but it is primarily present during the primary P4 rise. During the secondary P4 rise, PGFM can be used as a predictive marker for the timing of birth.

Estrogens have been described as remaining low and at baseline concentrations in the giant panda luteal phase. However in other species estrogens play a role in blastocyst implantation, maternal recognition of pregnancy, are produced by the placenta, and play a role in preparation for parturition.

We hypothesized that estrogens are not products of the corpus luteum (CL) in giant pandas and concentrations would be different in pregnancy when compared to pseudopregnancy. Our aim was to assess urinary estrogens across the luteal phase in giant pandas with an interest in the potential period of gestation, studying pregnancy, pseudopregnancy and non-birthing inseminated estrous cycles.

**Results**

**Estrous cycle hormones of the giant panda.** We first assessed whether luteal phase estrogen concentrations were related to CL function in the giant panda estrous cycle. The average concentrations of P4 and estrogen, corrected for urinary specific gravity (USpG) across the estrous cycle of all giant pandas in this study (n = 13) are displayed in Fig. 1. There is a clear pattern of P4 concentration across the luteal phase with a five-fold increase from the primary to the secondary rise. Unlike P4, after estrus there is not a clear pattern of estrogen concentrations (Fig. 1). P4 and estrogen concentrations did not correlate across the luteal phase of the cycle (r = −0.25, P = 0.43).

**Luteal phase comparison of pregnancy and pseudopregnancy.** We next assessed whether the concentrations of luteal phase hormones could distinguish between pregnant and pseudopregnant cycles. Table 1 describes the average area under the curve (AUC) for P4 and estrogen concentration profiles across the luteal phase of pregnancy (n = 3) and pseudopregnancy (n = 3). There were no significant differences between pregnancy and pseudopregnancy for P4 for any period of the luteal phase. For estrogens however, a significant increase was observed during pregnancy between secondary P4 rise pre- and post-PGFM spike periods (P < 0.005), and also between pregnancy and pseudopregnancy secondary P4 rise post-PGFM spike periods (P < 0.01; Table 1).

**Estrogens during the secondary progesterone rise.** As the estrogen concentrations were different in pregnant compared with pseudopregnant cycles, we examined the estrogen concentrations between secondary P4 rise pre- and post-PGFM spike periods in more detail. During the secondary P4 rise, estrogens in pregnancy showed an increasing profile for the final 29 ± 3 days of pregnancy (Fig. 2) and following the PGFM spike, estrogen concentrations increased 6 fold (Table 1). This allowed a nomogram to be developed to model the hormonal changes expected during pregnancy (Fig. 3A). This describes the Standard Error of the Mean (SEM) range of
estrogen/USpG for pregnancy (black dotted range) and pseudopregnancy (grey dotted range) and is plotted from the luteal PGFM spike, a time point which is known before the outcome of pregnancy is known.

**Validation of pregnancy nomogram.** Estrogen/USpG was further assessed in two further cycles with known outcomes, a pregnancy and pseudopregnancy, to validate the nomogram (Fig. 3A). In the cycle leading to a birth (Fig. 3B) the pattern was clearly in the pregnancy range and in the pseudopregnancy the pattern was that of a pseudopregnant individual (Fig. 3C).

**The nature of the estrogen rise at the end of gestation.** As the rise in estrogens before birth would be consistent with a placental source of the estrogen, we examined the concentrations of estriol as it is a major placental estrogen in several species, including women. Estriol's profile was not significantly different between pregnant and pseudopregnant cycles, and concentrations appeared to decrease in the final week of all cycles (data not shown).

**Using the nomogram to interrogate inseminated non-birth cycles.** We examined five non-birth cycles to determine if this could highlight whether there was a pregnancy and if there was any indication at what time a pregnancy failed using the nomogram (Fig. 4A). In one cycle (Fig. 4B) there was no evidence of pregnancy. However, in four cycles (Fig. 4C–F) there were intermediate estrogen concentrations with the deviation becoming clear between 16 and 18 days after the PGFM spike.

**Discussion**

Our study clearly illustrates that the measurement of urinary estrogens corrected for USpG provides noteworthy potential as a non-invasive biomarker of ongoing pregnancy in the giant panda.

---

**Table 1.** The mean Area Under the Curve (AUC) statistic for P4 and estrogens for the luteal phase, comparing pregnancy (n = 3) and pseudopregnancy (n = 3). There were no significant differences between pregnant and pseudopregnant P4. Estrogens were significantly increased in pregnancy between the secondary P4 rise pre- and post-PGFM spike periods, and between pregnancy and pseudopregnancy secondary P4 rise post-PGFM spike periods. The superscript letters indicate significant difference between estrous phases.

|                        | PROGESTERONE | ESTROGENS |
|------------------------|--------------|-----------|
| **Primary P4 Rise**    |              |           |
| PREGNANT               | 14.5         | 13.0      |
| PSEUDOPREGNANT         | 16.4         | 18.5      |
| **Secondary P4 Rise Pre-PGFM Spike** |       |           |
| PREGNANT               | 43.2         | 4.0*      |
| PSEUDOPREGNANT         | 21.5         | 1.6       |
| **Secondary P4 Rise Post-PGFM Spike** |       |           |
| PREGNANT               | 105.2        | 32.0b,b   |
| PSEUDOPREGNANT         | 95.4         | 6.7b      |

**Figure 2.** The mean fold change of estrogen/Urinary Specific Gravity (USpG) ± Standard Error of the Mean (SEM) during the secondary P4 rise in pregnancy (n = 3; solid black line) and pseudopregnancy (n = 3; solid grey line). Each point is a 5-day average, and plotted as days from birth/the end of the cycle. Birth/the end of the cycle is 0 on the x-axis. AUC analysis showed that these patterns were significantly different (P < 0.0001) following the PGFM spike.
Previous reports state that urinary estrogens remain unchanged for the duration of the luteal phase following estrus\(^4,10,11\), however we are able to identify significant changes correcting estrogens for USpG as an alternative to creatinine\(^21\), which has previously been used for urinary hormone correction in giant pandas. Creatinine (Cr), a muscle metabolite with fairly constant daily excretion, has been previously used as a marker of urine concentration for hormone correction in giant panda urine. However, there is a drive for pandas to increase weight during the primary P4 rise, and a decrease of activity and food intake with weight loss during the secondary P4 rise. These behavioural changes are paired with large fluctuations in Cr concentrations\(^21,22\). USpG can be utilised as an alternative\(^21\), particularly at this time, as it is affected by dietary or activity changes to a lesser extent than Cr. During the secondary P4 rise, we identified a 6-fold increase of estrogens following the initial PGFM spike in pregnancy, which lasts for 29 ± 3 days, until birth. Such an estrogen increase was not observed in pseudopregnant females. More particularly, the profiles of pregnancy and pseudopregnancy were able to be clearly resolved from each other during the final 2 weeks of the cycle.

The biphasic P4 profile cannot diagnose pregnancy as P4 originates from the corpus luteum (CL) which is present in all cyclic female pandas\(^23\). It has been previously shown that estrogens are low in abundance in the

---

**Figure 3.** Testing two estrous cycles’ estrogen/Urinary Specific Gravity (USpG) profiles using the nomogram. A = the black dotted range indicates pregnancy, the grey dotted range indicates pseudopregnancy. B = the results from a known birth (pregnancy) cycle, C = the results from a known pseudopregnancy. The x-axis represents days from the start of the PGFM spike, with 0 defined as the last day of baseline PGFM before the spike.
luteal phase\textsuperscript{4,10,11} and we have confirmed this. Nevertheless, in identifying no correlation between P4 and estrogen across the luteal phase, we suggest that the estrogens are not produced by the CL.

In contrast, we suggest that the increasing urinary estrogens measured during successful pregnancy is a biomarker of the placenta itself or of a placental product.

Figure 4. Testing five estrous cycles, which were inseminated but non-birth cycles, estrogen/Urinary Specific Gravity (USpG) profiles using the nomogram. A = the black dotted range indicates pregnancy, the grey dotted range indicates pseudopregnancy. B–F = the red line on each nomogram represents inseminated but non-birth cycles. The x-axis represents days from the start of the PGFM spike, with 0 defined as the last day of baseline PGFM before the spike.
Table 2. A summary of the thirteen estrous cycles from the five females included in the study, indicating the pandas which contributed towards the pregnant, pseudopregnant and non-birth groups, and the number of urine samples analysed for each female.

| Studbook (SB) # | # of pregnant cycles | # of pseudo-pregnant cycles | # of non-birth cycles | # of urine samples |
|----------------|----------------------|-----------------------------|-----------------------|-------------------|
| 473            | 2                    | 0                           | 0                     | 66                |
| 569            | 0                    | 1                           | 4                     | 539               |
| 723            | 1                    | 0                           | 0                     | 124               |
| 741            | 1                    | 1                           | 1                     | 221               |
| 884            | 0                    | 2                           | 0                     | 94                |

Materials and Methods

Sample collection. Urine samples were collected from five female giant pandas housed at RZSS Edinburgh Zoo, Scotland (SB569), Pairi Daiza, Belgium (SB741), Smithsonian’s National Zoological Park, Washington DC, USA (SB473), Ouwehands Dierenpark, The Netherlands (SB884), and Zoo Parc De Beauval, France (SB723). An average of 80 urine samples per cycle from thirteen ovulatory estrous cycles were available, representing 4 pregnancies, 4 true pseudopregnancies (non-mated and non-artificially inseminated (AI) cycles), and 5 inseminated but non-birth cycles (Table 2), collected between 2013 and 2018.

This study was performed on non-invasively collected urine samples which are collected daily, where possible, for reproductive monitoring, and which were aspirated from the floor of the enclosure in the absence of the animal during routine maintenance, and frozen at −20 °C. All animal-related work was conducted in line with the relevant national and international guidelines, and no specific ethical approval was required for this study.
Following the first thaw, samples were centrifuged (15 minutes at 2000g at room temperature), and were assessed for density by USpG prior to endocrine measurements. Urine from SB723 and SB741 were analysed at Ghent University. Urine from SB473, SB569 and SB884 were analysed at the University of Edinburgh. All urine samples were transported frozen from their respective zoological parks to the universities.

**Urinary Specific Gravity (USpG).** USpG was measured as previously described\(^2\) using a handheld digital refractometer (ATAGO, Japan), designed either for human (PAL-10S, range 1.000–1.060) or cat urine (PAL–USG (Cat), range 1.000–1.080). The use of either refractometer for the measurement of giant panda USpG has been validated previously\(^3\). The same refractometer was used for all samples of the same panda – SB723, 741 and 884 samples were measured with the PAL–USG; SB473 and 569 samples were measured with the PAL-10S. Briefly, deionised water (300 µL) calibrated the instrument prior to the measurement of USpG of the sample (300 µL). Hormones were corrected for USpG as described for giant pandas\(^3\), making use of the following formula\(^2\):

\[
\text{Estrogen corrected for USpG} = \text{Raw estrogen concentration} \times \left( \frac{\text{USpG target} - 1.000}{\text{USpG sample} - 1.000} \right)
\]

**Measurement of estrogens.** Estrogens in giant panda urine can be measured by metabolite assays for both oestrone-3-glucuronide (E1G) and oestrone-3-sulphate (E1S). In this study urine samples from SB473, 569 and 884 were measured only for E1G from SB723 only for E1S; and from SB741 for both E1G and E1S, this data was used to produce a conversion factor for E1S to E1G to allow all sample results to be comparable. E1G measurements were undertaken at the MRC Centre for Reproductive Health, University of Edinburgh, while E1S measurements were undertaken at the Laboratory of Chemical Analysis, Faculty of Veterinary Medicine, Ghent University. In addition, estriol, an estrogen known to be produced by the human placenta\(^1\),\(^9\),\(^20\),\(^28\), was also measured in urine samples in the final three weeks of the cycle. A total of 91 urine samples from 3 pregnant (n = 54 samples) and 3 pseudopregnant (n = 37 samples) cycles of 4 females (SB473, 569, 741, 884) were tested for estriol.

E1G was measured by E1G DetectX® Enzyme Immunoassay (EIA) Kit (K036-H5; Arbor Assays™, Ann Arbor, Michigan, USA) following the manufacturer’s protocol. Cross reactivities of 100%, 66.6%, 238%, 7.8%, 3.8% and 3.3% are reported for E1G, E1S, estrone, 17β-estradiol, estradiol-3-glucuronide and estradiol-3-sulphate respectively. The limit of detection was 8.76 pg/mL. Briefly, prepared standards, controls and urine (50 µL) were added in duplicate to the wells of a 96-well pre-coated plate (Goat Anti-Rabbit Immunoglobulin G (IgG)). Urine was diluted by a factor of 5 in Assay Buffer prior to analysis on the assay. E1G Enzyme Conjugate and E1G Antibody (25 µL each) were added to each well. Following incubation (2 hours, room temperature) each well was washed 4 times with prepared wash buffer (300 µL) and dried on paper towels. 3,3′,5,5′-Tetramethylbenzidine (TMB; 100 µL) was added to each well for 30 minutes of incubation in the dark at room temperature. The reaction was stopped by the addition of Stop Solution (50 µL). The absorbance was quantified at 450 nm on a LT-4500 Microplate Absorbance Reader (LabTech, Version 7 2010, Tecan Group Ltd., Switzerland). EIA readings were analysed using a 4 Parameter Logistic (4PLC) nonlinear regression model on MasterFlex ReaderFit Software (Version 2; Hitachi Solutions, USA). Inter- and intra-assay coefficients of variation (CV) were calculated to be 12.5% and 4.0% respectively.

E1S was measured as described by Wauters et al.\(^2\), using the Estrone DetectX® EIA Kit (K031-H1; Arbor Assays™, Ann Arbor, Michigan, USA), replacing the estrone standard with the E1S standard (C135–125 µL; Arbor Assays™, Ann Arbor, Michigan, USA). Cross reactivities of 100%, 112%, 65.5%, and 5% are reported for estrone, E1G, E1S and estradiol respectively. The limit of detection of the assay was 28.2 pg/mL. The assay was performed following the manufacturer’s protocol as described above; however samples were diluted in Assay Buffer by a factor of 10 for analysis. Inter- and intra-assay CVs were calculated as 10.5% and 6.0% respectively. In whole cycles where only E1S was measured, the data was converted to E1G through the use of a conversion factor (0.381). This conversion factor was determined by the analysis of 93 urine samples for both E1G and E1S that were compared to allow the determination of a conversion factor from E1S to E1G. There is a highly statistically significant (P < 0.0001) linear correlation (r = 0.889) between E1G and E1S measurements and the conversion factor ensured equivalent concentrations for analysis.

Estriol was measured using the Estriol DetectX® EIA Kit (K064-H5; Arbor Assays™, Ann Arbor, Michigan, USA). Cross reactivities of 100%, 57.16%, 38.5%, 6.77%, 0.03% and 0.02% were reported for estriol, oestradiol-3-glucuronide, oestradiol-3-sulphate, 16-epiestriol, 17β-estradiol and 17β-epiestriol respectively. The limit of detection of the assay was 6.81 pg/mL. The assay was performed following the manufacturer’s protocol as described above; urine samples were diluted in Assay Buffer by a factor of 2 for analysis. Inter- and intra-assay CVs were calculated as 14.2% and 11.9% respectively.

**Measurement of Progesterone.** P4 was measured using the Progesterone DetectX® EIA Kit (K025-H5; Arbor Assays™, Ann Arbor, Michigan, USA). Cross reactivities of 100%, 172%, 188%, 2.7%, 127%, 7% and 5.9% were reported for P4, 3β-hydroxyprogesterone, 3-hydroxyprogesterone, 11β-hydroxyprogesterone, 11-hydroxyprogesterone, 5-dihydroxyprogesterone and pregnenolone respectively. The limit of detection of the assay was 52.9 pg/mL. The assay was performed following the manufacturer’s guidelines as described above; urine samples were diluted in Assay Buffer by a factor of 10 until the secondary P4 rise when a factor of at least 100 was required. Inter- and intra-assay CVs were calculated as 13.8% and 2.0% respectively.

**Measurement of PGFM.** PGFM was measured using the PGFM DetectX® EIA Kit (K022-H5; Arbor Assays™, Ann Arbor, Michigan, USA). Cross reactivities of 100% and 1.5% were reported for PGFM and Prostaglandin E Metabolite respectively. The limit of detection of the assay was 46.2 pg/mL. The assay was validated previously\(^2\).}
performed following the manufacturer’s guidelines as described above; urine samples were diluted in Assay Buffer by a factor of 10 until peak P4 was reached, when a factor of 100 was required. Inter- and intra-assay CVs were calculated as 11.1% and 18.3% respectively.

**Data analysis.** The onset of estrus was defined as peak estrogen concentrations, with ovulation defined as a decrease in estrogens and an increase in P4. The onset of the primary P4 rise was defined as starting seven days post-estrus\(^21\). The onset of the secondary P4 rise was defined as being when the P4 concentration on two consecutive days was two standard deviations above the mean P4 concentration\(^5\). In pregnant pandas, the day of parturition was defined as the final day of the cycle. For pseudopregnant or non-birth cycles the date of the end of the cycle was calculated based on the PGFM profile; the end of cycle is defined as 24 days after the last baseline measurement of PGFM before the initial PGFM spike. One pregnancy and one pseudopregnancy were randomly assigned to a test paradigm, each of the other three cycles of pregnancy and pseudopregnancy were used to model differences between cycle outcomes.

In comparing P4 and estrogen between pregnancy and pseudopregnancy, data were standardised allowing for individual variation in baseline concentrations. AUC statistics were applied to each cycle for P4 and estrogen comparison of pregnant and pseudopregnant outcomes. The baseline for the AUC statistic was calculated as the mean primary rise value for each of estrogen and P4 concentrations. The average AUC for each phase of each hormone of each cycle was then used to determine the overall AUC for each phase of each hormone for both pregnancy (n = 3) and pseudopregnancy (n = 3).

AUC statistics were also applied when comparing the pregnancy and pseudopregnancy estrogen profiles during the secondary P4 rise in the pre- and post-PGFM periods.

When comparing estrogens within the secondary P4 rise, the estrogen data was standardised to ‘mean fold change of estrogen’. The average estrogen concentration for the duration of the primary P4 rise was calculated for each cycle. Each estrogen value was then divided by this average to determine the mean fold change of the sample. This allowed measurements of either E1G or E1S to be comparable for secondary P4 rise assessment without needing a conversion factor to analyse the data.

Statistical analysis was undertaken on GraphPad Prism (Version 7.02, GraphPad Software, Inc., California, USA). Parametric, non-paired, statistics were applied based on normality of the data being found by a Shapiro-Wilk test. Pearson’s correlation coefficient was applied to assess the correlation of P4 and estrogen across the estrous cycle. A one-way ANOVA with Tukey’s Multiple Comparisons was applied to compare the different reproductive phases of pregnant and pseudopregnant outcomes. Significance was defined as P < 0.05.

**Data Availability**

The datasets involved in this study can be requested from the corresponding author.

**References**

1. Swaisgood, R., Wang, D., Wei F. *Ailuropoda melanoleuca*. The IUCN Red List of Threatened Species 2016, e.T712A102080807, https://doi.org/10.2305/IUCN.UK.2016-2.RLTS.T712A4503386.en (2016).

2. Chen, Y.-P., Ellison, A. M. & Lu, Y. L. Establish a special conservation zone for the captive giant panda. *Ecosystem Health and Sustainability*. 4, 29–33 (2018).

3. Kersey, D. C. et al. Endocrine milieu of periestrus in the giant panda (*Ailuropoda melanoleuca*), as determined by non-invasive hormone measures. *Reprod. Fertil. Dev.* 22, 901–912 (2010).

4. Kersey, D. C. et al. The birth of a giant panda: tracking the biological factors that successfully contribute to conception through to postnatal development. *Theriogenology*. 85, 671–677 (2016).

5. Kersey, D. C. et al. Unique biphasic progestagen profile in parturient and non-parturient giant pandas (*Ailuropoda melanoleuca*) as determined by faecal hormone monitoring. *Reproduction*. 40, 183–193 (2010).

6. Zhang, H., Li, D., Wang, C. & Hull, V. Delayed implantation in giant pandas: the first comprehensive empirical evidence. *Reproduction*. 138, 979–986 (2009).

7. Roberts, B. M. et al. Use of urinary 13,14, dihydro-15-keto- proglandin F2α (PGFM) concentrations to diagnose pregnancy and predict parturition in the giant panda (*Ailuropoda melanoleuca*). *PLoS One*. 13, e0195599, https://doi.org/10.1371/journal.pone.0195599 (2018).

8. Sutherland-Smith, M., Morris, P. J. & Silverman, S. Pregnancy detection and fetal monitoring via ultrasonic in a giant panda (*Ailuropoda melanoleuca*). *Zoo Biol*. 23, 449–469 (2004).

9. Willis, E. L., Kersey, D. C., Durrant, B. S. & Kouba, A. J. The acute phase protein ceruloplasmin as a non-invasive marker of pseudopregnancy, pregnancy, and pregnancy loss in the giant panda. *PLoS One*. 6, e21159, https://doi.org/10.1371/journal.pone.0021159 (2011).

10. Hodges, J. K. et al. Aspects of the reproductive endocrinology of the female giant panda (*Ailuropoda melanoleuca*) in captivity with special reference to the detection of ovulation and pregnancy. *J. Zool*. 203, 253–267 (1984).

11. Chaudhuri, M. et al. Urinary steroid concentrations during the natural and gonadotrophin-induced estrus and pregnancy in the giant panda (*Ailuropoda melanoleuca*). *J Reprod. Fertil*. 88, 23–28 (1988).

12. Ma, W.-G., Song, H., Das, S. K., Paria, B. C. & Dey, S. K. Estrogen is a critical determinant that specifies the duration of the window of uterine receptivity for implantation. *PNAS*. 100, 2936–2968 (2003).

13. Bazer, F. W. & First, N. L. Pregnancy and Parturition. *J. Animal Sci.* 57, 425–460 (1983).

14. Ka, H., Seo, H., Choi, Y., Yoo, I., Han, J. Endometrial response to conceptus-derived estrogen and interleukin-1β at the time of implantation in pigs. *J Anim Sci Biotech*. 9, https://doi.org/10.1186/s40104-018-0259-8 (2018).

15. Ash, R. W. & Heap, R. B. Estrogen, progesterone, and corticosteroid concentrations in peripheral plasma of sows during pregnancy, parturition, lactation and after weaning. *J. Endocrinol*. 64, 141–154 (1975).

16. Challs, J. R. G., Heap, R. B. & Illingworth, D. V. Concentrations of estrogen and progesterone in the plasma of non-pregnant, pregnant and lactating guinea pigs. *J Endocrinol*. 51, 333–335 (1971).

17. Chambers, P. L. & Hearn, J. P. Peripheral plasma levels of progesterone, oestradiol-17β, oestrone, testosterone, androstenedione and chorionic gonadotrophin during pregnancy in the marmoset monkey. *Calithrix jaccus*. *J Reprod. Fertil*. 56, 23–32 (1979).

18. Siiteri, P. K. & MacDonald, P. V. Placental estrogen biosynthesis during human pregnancy. *J Clin. Endocrinol. Metab*. 26, 751–761 (1966).

19. Vannucci, S., Bocchi, C., Severi, F. M., Challsi, J. R. & Petraglia, F. Endocrinology of human parturition. *Ann. Endocrinol*. 77, 105–113 (2016).
20. Aoba, H. Urinary estriol as an index of placental function. Tohoku J Exp. Med. 89, 121–130 (1966).
21. Wauters, J. et al. Urinary specific gravity as an alternative for the normalisation of endocrine metabolite concentrations in giant panda (Ailuropoda melanoleuca) reproductive monitoring. PLoS ONE. 13, e0201420, https://doi.org/10.1371/journal.pone.0201420 (2018).
22. Owen, M. A., Czekala, N. M., Swaisgood, R. R., Steinman, K. & Lindburg, D. G. Seasonal and diurnal dynamics of glucocorticoids and behaviour in giant pandas. Ursus. 16, 208–221.
23. Brown, J. L. Comparative ovarian function and reproductive monitoring of endangered mammals. Theriogenology. 109, 2–13 (2018).
24. Aralla, M., Groppetti, D., Caldarini, L., Cremonesi, F. & Arrighi, S. Morphological evaluation of the placenta and fetal membranes during canine pregnancy from early implantation to term. Res Vet Sci 95, 15–22.
25. Braun, B. C., Zschokkelt, L., Dehnhard, M. & Jewgenow, K. Progesterone and estradiol in cat placenta – Biosynthesis and tissue concentration. J. Steroid Biochem. Mol. Biol. 132, 295–302 (2012).
26. Tsuji, T. et al. Immunolocalisation of steroidogenic enzymes in the corpus luteum and placenta of the Japanese black bear, Ursus thibetanus japonicas, during pregnancy. Reproduction 121, 587–594 (2001).
27. Miller, R. C. et al. Comparison of specific gravity and creatinine for normalising urinary reproductive hormone concentrations. Clin. Chem. 50, 924–932 (2004).
28. Morel, Y. et al. Evolution of steroids during pregnancy: maternal, placental and fetal synthesis. Ann. Endocrinol. 77, 82–89 (2016).

Acknowledgements
The authors would like to thank and acknowledge the support of all of the zoological parks and their giant panda teams who have been involved in diligent and thorough urine sample collection which has allowed this study to take place. In particular Alison Maclean and the panda team at RZSS Edinburgh Zoo for their sample collecting efforts over the past seven years; and to Dr. Tim Bouts and Liu Yang of Pairi Daiza, Belgium; to Dr. Baptiste Mulot and Antoine Leclerc of ZooParc de Beauval, France; to José Kok of Ouwehands Dierenpark, The Netherlands; and to Dr. David Wildt and Dr. Janine Brown of Smithsonian Conservation Biology Institute, USA. The authors would also like to thank Prof. Dr. Lynn Vanhaecke and Dirk Stockx for the provision of equipment and assay assistance at Ghent University. K.S.W. is supported by the University of Edinburgh and the MRC Centre for Reproductive Health (MR/N022556/1).

Author Contributions
All authors undertook experimental design and conceptualisation. K.S.W., J.W., I.V. and S.G. were involved with data curation. K.S.W., J.W. and W.C.D. undertook data analysis. All authors were involved with writing and editing the article manuscript.

Additional Information
Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019